Call Us: 1 (800) 647 6100

6900 Kingspointe Pkwy, Orlando, FL 32819, US

Open in Google Maps


6900 Kingspointe Pkwy, Orlando, FL 32819, US

Open in Google Maps

XYMOGEN Surpasses Seven Million Dollar Month Milestone

XYMOGEN Surpasses Seven Million Dollar Month Milestone
XYMOGEN Surpasses Seven Million Dollar Month Milestone

XYMOGEN Surpasses Seven Million Dollar Month Milestone

  • by Admin
  • Thursday, February 26, 2015

ORLANDO, Fla. -- February 26, 2015 -- Orlando-based health sciences company XYMOGEN has announced it surpassed the Seven Million Dollar Month Revenue Milestone for January-2015. This represents the third consecutive January in which the company surpassed a Million-Dollar Milestone, reaching $5 million and $6 million in 2013 and 2014, respectively.

"This is a very promising start to 2015, and I don't see this dollar mark as a one-time occurrence," said XYMOGEN CEO Brian Blackburn. "With many initiatives in place as we launch 2015, I believe XYMOGEN will eclipse the $8 million mark in the third quarter of this year."

The company's revenues have been steadily increasing since their inception in 2003. Even at a time when few companies are growing, XYMOGEN has seen consistent sales growth for 44 consecutive quarters, and realized over 500 percent growth in the past five years. XYMOGEN's annual sales have skyrocketed from just over $5.2 million in 2004 to more than $68 million by the end of 2014.

"To really put things into perspective, our net sales for this one month were 30 percent larger than our entire first full year in 2004," Blackburn said. "While XYMOGEN has diversified its business model to include Contract Manufacturing and International Sales, the vast majority of growth came from the North American Practitioner-Channel."

XYMOGEN, who began selling their formulas internationally with Canada in 2012, now has product available in more than 16 different countries, across six continents. Blackburn believes the company's international growth is extremely important, as by reaching beyond the United States into international markets, XYMOGEN can achieve their ultimate goal to positively impact the health of people worldwide. "XYMOGEN was founded based upon what we felt were voids in the Practitioner-Channel of the nutracetutical industry," Blackburn said. "In particular, XYMOGEN focused on Exclusive and Patented Ingredients, Evidence-Based Dosing, and a strategy to eliminate the Internet sale of its professional formulas. XYMOGEN's ePedigree program has been highly successful with only 16 of its 230+ formulas available on the Internet as of January 31, 2015."

The company began manufacturing their own formulas when they opened their new, 136,000-square-foot, state-of-the-art manufacturing facility and headquarters in 2012. Since that time, the facility has been GMP (Good Manufacturing Practices) and GMP for Sport registered with NSF International, one of the most respected independent product testing organizations. They also expect to be certified by the Australia Therapeutic Goods Association early in 2015.

To ensure future success, the company continues to improve their manufacturing capabilities and invest in practitioner education, international expansion and security initiatives, such as the aforementioned ePedigree track and trace program. These efforts, according to Blackburn, will allow the company to remain the fastest-growing company in the marketplace and guarantee that XYMOGEN's formulas are the most thoroughly researched and tested that the industry has to offer.

Tags: XYMOGEN Seven Million

Share This Post:


Latest Tweets

Become a XYMOGEN Insider

Join our mailing list.
Interested in receiving special offers, access to exclusive webinars, seminars, up-to-date industry news, and so much more? Sign up for our FREE newsletter and get started today!

BONUS: As a XYMOGEN Insider, you will also get a FREE digital copy of The Rise of Integrative Health & Medicine—The Milestones: 1963–Present by Glenn Sabin and Taylor Walsh.


Global Headquarters
Contact Us


NSF Certified
© 2023 XYMOGEN®. All right reserved.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.